Exagen Inc.

NasdaqGM:XGN Stock Report

Market Cap: US$72.3m

Exagen Management

Management criteria checks 2/4

Exagen's CEO is John Aballi, appointed in Oct 2022, has a tenure of 2.08 years. total yearly compensation is $931.95K, comprised of 56.3% salary and 43.7% bonuses, including company stock and options. directly owns 1.95% of the company’s shares, worth $1.41M. The average tenure of the management team and the board of directors is 2 years and 4.9 years respectively.

Key information

John Aballi

Chief executive officer

US$932.0k

Total compensation

CEO salary percentage56.3%
CEO tenure2.1yrs
CEO ownership2.0%
Management average tenure2yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified

Sep 06
Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified

Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Aug 07
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price

Jul 13
Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price

Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?

May 21
Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?

Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Mar 26
Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Mar 22
Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry

Jul 21
Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry

Exagen appoints John Aballi as CEO

Oct 17

Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers

Aug 10
Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers

Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?

Jul 26
Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?

Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?

Apr 05
Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Dec 03
Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Aug 06
Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price

Apr 07
Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price

Is Exagen (NASDAQ:XGN) Using Too Much Debt?

Mar 03
Is Exagen (NASDAQ:XGN) Using Too Much Debt?

Exagen issues preliminary testing revenue ahead of ICT chat

Jan 11

Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?

Jan 05
Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?

Exagen (XGN) Investor Presentation - Slideshow

Nov 20

CEO Compensation Analysis

How has John Aballi's remuneration changed compared to Exagen's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$17m

Jun 30 2024n/an/a

-US$17m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$932kUS$525k

-US$24m

Sep 30 2023n/an/a

-US$32m

Jun 30 2023n/an/a

-US$35m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$1mUS$111k

-US$47m

Compensation vs Market: John's total compensation ($USD931.95K) is above average for companies of similar size in the US market ($USD650.80K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Aballi (39 yo)

2.1yrs

Tenure

US$931,950

Compensation

Mr. John Aballi serves as President, Chief Executive Officer and Director at Exagen Inc. since October 17, 2022 and served as its Interim Chief Financial Officer since August 2024 until August 31, 2024. Mo...

Leadership Team

NamePositionTenureCompensationOwnership
Tina Nova
Executive Chairman of the Board of Directors5.3yrsUS$132.81k0%
$ 0
John Aballi
CEO, President & Director2.1yrsUS$931.95k1.95%
$ 1.4m
Kamal Adawi
Corporate Secretary7.2yrsUS$915.09k0.30%
$ 218.9k
Jeffrey Black
Chief Financial Officerless than a yearno data1.58%
$ 1.1m
Ryan Douglas
Investors Relations Officerno datano datano data
Andrew Concoff
Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board2.1yrsno datano data
Michael Nerenberg
Chief Medical Officer1.5yrsno datano data

2.0yrs

Average Tenure

55yo

Average Age

Experienced Management: XGN's management team is not considered experienced ( 2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Tina Nova
Executive Chairman of the Board of Directors5.3yrsUS$132.81k0%
$ 0
John Aballi
CEO, President & Director2.1yrsUS$931.95k1.95%
$ 1.4m
Andrew Concoff
Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board4.9yrsno datano data
Kenneth Bloom
Member of Breast Cancer Advisory Boardno datano datano data
Mark Pegram
Member of Breast Cancer Advisory Boardno datano datano data
Bruce Robertson
Independent Director5.3yrsUS$33.75kno data
Thomas Williams
Member of Breast Cancer Advisory Boardno datano datano data
Michael Press
Member of Breast Cancer Advisory Boardno datano datano data
Lyndsay Harris
Member of Breast Cancer Advisory Boardno datano datano data
Raymond Tubbs
Member of Breast Cancer Advisory Boardno datano datano data
Arthur Weinstein
Chairman of Scientific Advisory Board4.9yrsUS$130.00kno data
Frank Stokes
Independent Director3.4yrsUS$82.70k0%
$ 0

4.9yrs

Average Tenure

63.5yo

Average Age

Experienced Board: XGN's board of directors are considered experienced (4.9 years average tenure).